Santen Pharmaceutical Co., Ltd.

Masaki Sonoda

Masatsugu Nakamura

Mitsuaki Kuwano

Yoko Fukui

Koji Inagaki

Tatsuo Ikei

Kazuhiro Hosoi

Akiko Sakatani

Mikiko Saito

Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.

Ophthalmic solution comprising Diquafosol

Ophthalmic solution comprising diquafosol

Growing community of inventors

Osaka, Japan

Masaki Sonoda